Novartis Ag (NVS) Short term Debt (2009 - 2026)

Novartis Ag (NVS) has 12 years of Short term Debt data on file, last reported at -$19.0 million in Q1 2026.

• Quarterly Short term Debt changed N/A year-over-year to -$19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.0 million (changed N/A YoY) and the FY2025 annual result came in at $794.0 million, up 23.68% from the prior year.
• Short term Debt retreated to -$19.0 million in Q1 2026 per NVS's latest filing, from $794.0 million in the prior quarter.
• The five-year high for Short term Debt was $8.3 billion in Q2 2025, with the low at -$1.1 billion in Q2 2022.
• Average Short term Debt over 5 years is $3.1 billion, with a median of $718.0 million recorded in 2024.
• Year-over-year, Short term Debt tumbled 111.85% in 2022 and surged 871.07% in 2023.
• Novartis Ag's Short term Debt stood at $5.9 billion in 2022, then plunged by 89.48% to $624.0 million in 2023, then climbed by 2.88% to $642.0 million in 2024, then gained by 23.68% to $794.0 million in 2025, then sank by 102.39% to -$19.0 million in 2026.
• Business Quant data shows NVS's Short term Debt at -$19.0 million in Q1 2026, $794.0 million in Q4 2025, and -$9.0 million in Q3 2025.